10 of the 20 Top Pharmaceutical Companies
That’s who trusts EntityRisk’s combination of globally recognized health economics and policy expertise with advanced modeling software to identify the highest economically justifiable price and prioritize evidence investments
The EntityRisk Advantage
Unmatched Expertise
Renowned health economics, policy, and data sciences experts
Modeling Platform
Powerful, fast, transparent software for dynamic models with intuitive visualization
Commercial Impact
Identify defensible prices, measure evidence ROI, and prove your product’s value
Dana Goldman, PhD
Co-founder, Scientific Advisor
Founding Director, USC Schaeffer Institute for Public Policy & Goverment Service
Neal Masia, PhD
Co-Founder, CEO
Adjunct Professor, Columbia University
Former VP, Pfizer
Darius Lakdawalla, PhD
Co-Founder, Chief Scientific Officer
Chief Scientific Officer, USC Leonard D. Schaeffer Center for Health Policy and Economics
EntityRisk’s
PROVEN™ Platform
Build or expand your capacity for accurate, flexible and rapid value calculations through every customized instance of EntityRisk’s PROVEN™ Platform. Our platform, backed by decades of research, embeds the collective expertise of a world-class team and scales it on demand.
ValueML™
Simulate the distribution of supportable “value-based” prices and cost-effectiveness outcomes using a broad range of value assessment frameworks to support engagement with reimbursement authorities and customers
CommercialML™
Support go-to-market pricing and value-based care strategies; forecast and quantify the commercial revenue opportunity and downside risks under all efficacy and marketplace competition scenarios
EvidenceML™
Simulate the expected commercial opportunities and downside risks from alternative clinical and real-world evidence-generation strategies from Phase 2 through post-launch to optimize endpoint selection and evidence generation
PriceML™
Predict the likely distribution of real-world net prices for any given target product profile or efficacy scenario
OutcomesML™
Forecast the empirical distribution of real-world clinical effectiveness for pipeline candidates or newly launched medicines to support commercial decision making and/or customer engagement